X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 25, 2024
Details:
The Company intends to use the net proceeds to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
Anaphylm (epinephrine) is a polymer matrix-based epinephrine prodrug candidate product. It is being evaluated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Anaphylm (epinephrine) is an adrenergic receptor agonist hormone drug candidate. It is being evaluated for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Libervant™ (diazepam) buccal film is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity assignment in patients between two and five years of age.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Libervant
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Anaphylm (AQST-109) is a polymer matrix-based epinephrine prodrug candidate product administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine for the treatment of severe allergy and anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Anaphylm (AQST-109) is a polymer matrix-based epinephrine prodrug candidate product administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine for the treatment of Severe allergy and anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Anaphylm (epinephrine, previously known as AQST-109) acts on alpha-1 receptors, induces increased vascular smooth muscle contraction, pupillary dilator muscle contraction, and intestinal sphincter muscle contraction.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Anaphylm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Under the expanded agreement, Pharmanovia will cover the Additional Global Markets for Libervant™ (diazepam) buccal film, a benzodiazepine intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Libervant
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atnahs Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 29, 2023
Details:
AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: AQST-109
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
